NEW YORK (GenomeWeb News) - MDS has signed a definitive agreement to buy Molecular Devices, a maker of high-content screening, cellular analysis, and biochemical testing tools, for $615 million in cash, the companies said today.
 
The agreement calls for MDS to pay $35.50 per share for all of Molecular Devices’ common stock. The boards of both companies have approved the transaction.
 
MDS shares closed at $23.88 on Friday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.